Premium
TRAIL and TRAIL receptors in patients with laryngeal cancer
Author(s) -
Erkul Evren,
Kucukodaci Zafer,
Pinar Dogan,
Gungor Atila,
Alparslan Babayigit Mustafa,
Kurt Onuralp,
Cincik Hakan
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24035
Subject(s) - immunohistochemistry , medicine , perineural invasion , lymph node , stage (stratigraphy) , head and neck cancer , receptor , pathology , cancer , carcinoma , tumor necrosis factor alpha , oncology , t stage , staining , biology , paleontology
Background Tumor necrosis factor–related associated‐inducing ligand (TRAIL) is a death ligand currently under clinical trials for laryngeal carcinoma. Methods Paraffin‐embedded tissues from 40 patients with laryngeal carcinoma and 20 patients with benign laryngeal pathologies were retrospectively analyzed using immunohistochemistry in terms of distribution and intensity, and for final analysis of immunoreactivity of receptors, H‐score was used. The study group was assessed in terms of localization, lymph node staging, tumor stage, overall survival, disease‐free survival, locoregional control, perineural invasion, and vascular invasion. Results The H‐score of decoy‐R2 (DcR2) staining were increased significantly in tumor tissue ( p = .04). A significantly greater increase in terms of H‐score of DR5 receptor staining ( p = .06) was detected in tumor tissue. Conclusion TRAIL‐mediated gene therapy may not be effective. Indeed, the findings may indicate treatment resistance. TRAIL and TRAIL receptor levels were not associated with prognosis © 2015 Wiley Periodicals, Inc. Head Neck 38 : E535–E541, 2016